Skip to main content
Top
Published in: Journal of Interventional Cardiac Electrophysiology 1/2016

01-10-2016

Measuring quality in electrophysiology

Authors: Daniel J. Friedman, Sana M. Al-Khatib

Published in: Journal of Interventional Cardiac Electrophysiology | Issue 1/2016

Login to get access

Abstract

The evolving healthcare environment demands optimally measured quality of care. Performance measures are increasingly being used for quality improvement, public reporting, and reimbursement determinations. The National Quality Forum has created rigorous criteria for the evaluation of potential performance measures across medical fields. The Heart Rhythm Society has championed the development of four separate electrophysiology (EP)-specific performance measures: implantable cardioverter defibrillator complication rate, cardiac tamponade and/or pericardiocentesis following atrial fibrillation ablation, infection within 180 days of a cardiac implantable electronic device implantation, replacement, or revision, and in-person evaluation following a cardiac implantable electronic device implantation. National registries serve a key role in developing performance measures and facilitating quality improvement, particularly as they provide improved granularity and accuracy of data compared with administrative claims data. All performance measures demand continued reassessment as technology and performance gaps change and as unintended consequences may arise.
Literature
4.
go back to reference Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators (1991). The New England Journal of Medicine, 325(5), 293–302. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators (1991). The New England Journal of Medicine, 325(5), 293–302.
5.
go back to reference Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) (1999). Lancet, 353(9169), 2001–2007. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) (1999). Lancet, 353(9169), 2001–2007.
6.
go back to reference Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors (1992). The New England Journal of Medicine, 327(10), 685–691. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors (1992). The New England Journal of Medicine, 327(10), 685–691.
7.
go back to reference Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., et al. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. The New England Journal of Medicine, 334(21), 1349–1355.CrossRefPubMed Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., et al. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. The New England Journal of Medicine, 334(21), 1349–1355.CrossRefPubMed
10.
go back to reference Dodson, J. A., Reynolds, M. R., Bao, H., Al-Khatib, S. M., Peterson, E. D., Kremers, M. S., et al. (2014). Developing a risk model for in-hospital adverse events following implantable cardioverter-defibrillator implantation: a report from the NCDR (National Cardiovascular Data Registry). Journal of the American College of Cardiology, 63(8), 788–796.CrossRefPubMed Dodson, J. A., Reynolds, M. R., Bao, H., Al-Khatib, S. M., Peterson, E. D., Kremers, M. S., et al. (2014). Developing a risk model for in-hospital adverse events following implantable cardioverter-defibrillator implantation: a report from the NCDR (National Cardiovascular Data Registry). Journal of the American College of Cardiology, 63(8), 788–796.CrossRefPubMed
11.
go back to reference Prutkin, J. M., Reynolds, M. R., Bao, H., Curtis, J. P., Al-Khatib, S. M., Aggarwal, S., et al. (2014). Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the national cardiovascular data registry. Circulation, 130(13), 1037–1043.CrossRefPubMed Prutkin, J. M., Reynolds, M. R., Bao, H., Curtis, J. P., Al-Khatib, S. M., Aggarwal, S., et al. (2014). Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the national cardiovascular data registry. Circulation, 130(13), 1037–1043.CrossRefPubMed
12.
go back to reference Lewis, W. R., Piccini, J. P., Turakhia, M. P., Curtis, A. B., Fang, M., Suter, R. E., et al. (2014). Get with the guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation. Circulation. Cardiovascular Quality and Outcomes, 7(5), 770–777.CrossRefPubMed Lewis, W. R., Piccini, J. P., Turakhia, M. P., Curtis, A. B., Fang, M., Suter, R. E., et al. (2014). Get with the guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation. Circulation. Cardiovascular Quality and Outcomes, 7(5), 770–777.CrossRefPubMed
14.
go back to reference Krumholz, H. M., Herrin, J., Miller, L. E., Drye, E. E., Ling, S. M., Han, L. F., et al. (2011). Improvements in door-to-balloon time in the United States, 2005 to 2010. Circulation, 124(9), 1038–1045.CrossRefPubMedPubMedCentral Krumholz, H. M., Herrin, J., Miller, L. E., Drye, E. E., Ling, S. M., Han, L. F., et al. (2011). Improvements in door-to-balloon time in the United States, 2005 to 2010. Circulation, 124(9), 1038–1045.CrossRefPubMedPubMedCentral
15.
go back to reference McCabe, J. M., Kennedy, K. F., Eisenhauer, A. C., Waldman, H. M., Mort, E. A., Pomerantsev, E., et al. (2014). Reporting trends and outcomes in ST-segment-elevation myocardial infarction national hospital quality assessment programs. Circulation, 129(2), 194–202.CrossRefPubMed McCabe, J. M., Kennedy, K. F., Eisenhauer, A. C., Waldman, H. M., Mort, E. A., Pomerantsev, E., et al. (2014). Reporting trends and outcomes in ST-segment-elevation myocardial infarction national hospital quality assessment programs. Circulation, 129(2), 194–202.CrossRefPubMed
16.
go back to reference Wimmer, N. J., Cohen, D. J., Wasfy, J. H., Rathore, S. S., Mauri, L., & Yeh, R. W. (2014). Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable? American Heart Journal, 168(1), 103–109.CrossRefPubMedPubMedCentral Wimmer, N. J., Cohen, D. J., Wasfy, J. H., Rathore, S. S., Mauri, L., & Yeh, R. W. (2014). Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable? American Heart Journal, 168(1), 103–109.CrossRefPubMedPubMedCentral
17.
go back to reference Gasparini, M., Proclemer, A., Klersy, C., Kloppe, A., Lunati, M., Ferrer, J. B., et al. (2013). Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA, 309(18), 1903–1911.CrossRefPubMed Gasparini, M., Proclemer, A., Klersy, C., Kloppe, A., Lunati, M., Ferrer, J. B., et al. (2013). Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA, 309(18), 1903–1911.CrossRefPubMed
18.
go back to reference Moss, A. J., Schuger, C., Beck, C. A., Brown, M. W., Cannom, D. S., Daubert, J. P., et al. (2012). Reduction in inappropriate therapy and mortality through ICD programming. The New England Journal of Medicine, 367(24), 2275–2283.CrossRefPubMed Moss, A. J., Schuger, C., Beck, C. A., Brown, M. W., Cannom, D. S., Daubert, J. P., et al. (2012). Reduction in inappropriate therapy and mortality through ICD programming. The New England Journal of Medicine, 367(24), 2275–2283.CrossRefPubMed
19.
go back to reference Varma, N., Piccini, J. P., Snell, J., Fischer, A., Dalal, N., & Mittal, S. (2015). The relationship between level of adherence to automatic wireless remote monitoring and survival in pacemaker and defibrillator patients. Journal of the American College of Cardiology, 65(24), 2601–2610.CrossRefPubMed Varma, N., Piccini, J. P., Snell, J., Fischer, A., Dalal, N., & Mittal, S. (2015). The relationship between level of adherence to automatic wireless remote monitoring and survival in pacemaker and defibrillator patients. Journal of the American College of Cardiology, 65(24), 2601–2610.CrossRefPubMed
20.
go back to reference Saxon, L. A., Hayes, D. L., Gilliam, F. R., Heidenreich, P. A., Day, J., Seth, M., et al. (2010). Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation, 122(23), 2359–2367.CrossRefPubMed Saxon, L. A., Hayes, D. L., Gilliam, F. R., Heidenreich, P. A., Day, J., Seth, M., et al. (2010). Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation, 122(23), 2359–2367.CrossRefPubMed
21.
go back to reference Slotwiner, D., Varma, N., Akar, J. G., Annas, G., Beardsall, M., Fogel, R. I., et al. (2015). HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Heart Rhythm, 12(7), e69–e100.CrossRefPubMed Slotwiner, D., Varma, N., Akar, J. G., Annas, G., Beardsall, M., Fogel, R. I., et al. (2015). HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Heart Rhythm, 12(7), e69–e100.CrossRefPubMed
22.
go back to reference Wilkoff, B. L., Fauchier, L., Stiles, M. K., Morillo, C. A., Al-Khatib, S. M., Almendral, J., et al. (2016). 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm, 13(2), e50–86. doi:10.1016/j.hrthm.2015.11.018. Wilkoff, B. L., Fauchier, L., Stiles, M. K., Morillo, C. A., Al-Khatib, S. M., Almendral, J., et al. (2016). 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm, 13(2), e50–86. doi:10.​1016/​j.​hrthm.​2015.​11.​018.
Metadata
Title
Measuring quality in electrophysiology
Authors
Daniel J. Friedman
Sana M. Al-Khatib
Publication date
01-10-2016
Publisher
Springer US
Published in
Journal of Interventional Cardiac Electrophysiology / Issue 1/2016
Print ISSN: 1383-875X
Electronic ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-016-0118-5

Other articles of this Issue 1/2016

Journal of Interventional Cardiac Electrophysiology 1/2016 Go to the issue